Generic drugs | Intellepedia

Cancerous Battle: Novartis and NATCO clash over Eltrombopag

In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176).

Patent Suit over Viagra

Pfizer has sued Watson Laboratories to delay generic Viagra, leveraging the Hatch-Waxman Act and its patents. This case examines Pfizer’s legal strategy and the implications for generic competition in the pharmaceutical market.

Generication of Public Interest

This article explores how public interest has guided Indian patent law, often supporting generic drug companies over innovators. It argues for a balanced approach to public interest that considers both affordability and pharmaceutical innovation.

Pharmaceutical Business Strategy – A Brand Name Perspective

The post explores how brand name drug companies exploit regulatory provisions to maintain market dominance during generic drug challenges. It details the legal and procedural mechanisms involved, focusing on the strategic use of the 30 month stay period under the Hatch Waxman Act.

UNDP Issues Guidelines For Pharmaceutical Patent Examination

The UNDP has issued new guidelines aimed at strengthening pharmaceutical patent examination with an emphasis on public health. The guidelines advocate for stricter standards and the use of TRIPS flexibilities to curb evergreening and improve access to medicines.

Lee and BDR decision – the End of Compulsory Licenses?!

The Lee and BDR decisions signal a shift in the landscape of compulsory licensing in India. This post examines the legal and policy developments leading to these outcomes, highlighting their implications for the Indian pharmaceutical industry.

IPR and Access to Affordable Medicines: How affordable are We?

This post examines the complex interaction between intellectual property rights and access to affordable medicines in India. It provides a legal analysis of policy challenges and judicial decisions, highlighting the ongoing balance between innovation and public access to healthcare.

Extension of Waiver for Pharma Patents until 2033 A.D.

The WTO has extended the waiver on pharmaceutical patent enforcement for least developed countries until 2033. This move ensures continued access to affordable generics from India and highlights the ongoing tension between patient access and patent rights.

Merck v. Glenmark – A Bitter Battle of Pills

The Delhi High Court restrained Glenmark from manufacturing and marketing generic versions of Merck’s patented antidiabetic drugs. This case underscores key principles of Indian patent law and the balance between patent rights and public interest.

Gilead, IPA, Natco & The Bells of Harmony

The post examines the collaboration between Gilead, IPA, and Natco Pharma regarding the sofosbuvir patent in India. It analyses how voluntary licensing and innovative policies are improving access to affordable medicines while balancing public health and patent rights.